{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:05:43Z","timestamp":1767722743677,"version":"3.48.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Viatris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06122-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:57:04Z","timestamp":1767718624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Doxazosin versus tamsulosin for the treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS\/BPH): systematic literature review and network meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Matthias","family":"Oelke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Nicolas","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishveen","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R. W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"3","key":"6122_CR1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132(3):474\u2013479","journal-title":"J Urol"},{"issue":"27","key":"6122_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000974","volume":"94","author":"JQ Yuan","year":"2015","unstructured":"Yuan JQ, Mao C, Wong SY et al (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore) 94(27):e974","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"6122_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203479","volume":"13","author":"JH Kim","year":"2018","unstructured":"Kim JH, Baek MJ, Sun HY et al (2018) Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: a meta-analysis. PLoS ONE 13(10):e0203479","journal-title":"PLoS ONE"},{"issue":"4","key":"6122_CR4","first-page":"S83","volume":"12","author":"MM Issa","year":"2006","unstructured":"Issa MM, Fenter TC, Black L, Grogg AL, Kruep EJ (2006) An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care 12(4):S83-89","journal-title":"Am J Manag Care"},{"issue":"1","key":"6122_CR5","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D (2024) Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep 14(1):11116","journal-title":"Sci Rep"},{"issue":"11","key":"6122_CR6","doi-asserted-by":"publisher","first-page":"e754","DOI":"10.1016\/S2666-7568(22)00213-6","volume":"3","author":"AF Awedew","year":"2022","unstructured":"Awedew AF, Han H, Abbasi B et al (2022) The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Healthy Longev 3(11):e754\u2013e776","journal-title":"Lancet Healthy Longev"},{"issue":"1","key":"6122_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12894-024-01582-w","volume":"24","author":"Z Ye","year":"2024","unstructured":"Ye Z, Wang J, Xiao Y, Luo J, Xu L, Chen Z (2024) Global burden of benign prostatic hyperplasia in males aged 60\u201390 years from 1990 to 2019: results from the global burden of disease study 2019. BMC Urol 24(1):193","journal-title":"BMC Urol"},{"issue":"4","key":"6122_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0302-2838(02)00354-8","volume":"42","author":"KMC Verhamme","year":"2002","unstructured":"Verhamme KMC, Dieleman JP, Bleumink GS, van der Lei J, Sturkenboom MCJM (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care\u2014the Triumph Project. Eur Urol 42(4):323\u2013328","journal-title":"Eur Urol"},{"issue":"1","key":"6122_CR9","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.eururo.2013.03.004","volume":"64","author":"M Oelke","year":"2013","unstructured":"Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64(1):118\u2013140","journal-title":"Eur Urol"},{"issue":"5","key":"6122_CR10","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0302-2838(03)00376-2","volume":"44","author":"KMC Verhamme","year":"2003","unstructured":"Verhamme KMC, Dieleman JP, Bleumink GS, Bosch JLHR, Stricker BHC, Sturkenboom MCJM (2003) Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph Project. Eur Urol 44(5):539\u2013545","journal-title":"Eur Urol"},{"issue":"1","key":"6122_CR11","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","volume":"57","author":"CG Roehrborn","year":"2010","unstructured":"Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 57(1):123\u2013131","journal-title":"Eur Urol"},{"issue":"2","key":"6122_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S1569-9056(04)90505-2","volume":"29","author":"CR Chapple","year":"1996","unstructured":"Chapple CR (1996) Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29(2):129\u2013144","journal-title":"Eur Urol"},{"issue":"1","key":"6122_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000019919","volume":"36","author":"B Djavan","year":"1999","unstructured":"Djavan B, Marberger M (1999) A Meta-Analysis on the Efficacy and Tolerability of \u03b11-Adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction. Eur Urol 36(1):1\u201313","journal-title":"Eur Urol"},{"issue":"1","key":"6122_CR14","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/00365599309180412","volume":"27","author":"MM Christensen","year":"1993","unstructured":"Christensen MM, Holme JB, Rasmussen PC et al (1993) Doxazosin treatment in patients with prostatic obstruction. Scand J Urol Nephrol 27(1):39\u201344","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"6122_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000474321","volume":"24","author":"RA Janknegt","year":"1993","unstructured":"Janknegt RA, Chapple CR (1993) Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol 24(3):319\u2013326","journal-title":"Eur Urol"},{"issue":"11","key":"6122_CR16","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/j.1742-1241.2011.02759.x","volume":"65","author":"MS Chung","year":"2011","unstructured":"Chung MS, Lee SH, Park KK, Yoo SJ, Chung BH (2011) Comparative rapid onset of efficacy between doxazosin gastrointestinal therapeutic system and tamsulosin in patients with lower urinary tract symptoms from benign prostatic hyperplasia: a multicentre, prospective, randomised study. Int J Clin Pract 65(11):1193\u20131199","journal-title":"Int J Clin Pract"},{"key":"6122_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/sj.pcan.4500410","volume":"3","author":"R Kirby","year":"2000","unstructured":"Kirby R, Andersson KE, Lepor H, Steers WD (2000) \u03b11-Adrenoceptor selectivity and the treatment of benign prostatic hyperplasia and lower urinary tract symptoms. Prostate Cancer Prostatic Dis 3:76","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"6122_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/(SICI)1097-0045(19970915)33:1<55::AID-PROS9>3.0.CO;2-8","volume":"33","author":"CD Richardson","year":"1998","unstructured":"Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA (1998) Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned \u03b11-adrenergic receptor subtypes. Prostate 33(1):55\u201359","journal-title":"Prostate"},{"key":"6122_CR19","unstructured":"Urology Aao. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/benign-prostatic-hyperplasia-(bph)-guideline"},{"key":"6122_CR20","unstructured":"Gravas S, Cornu JN, Drake MJ, et al (2018) EAU Guidelines on Management of Non-neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO). Arnhem, The Netherlands: EAU Guidelines Office"},{"key":"6122_CR21","unstructured":"Urology EAo. EAU guidelines Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) 2024 Available from: https:\/\/uroweb.org\/guidelines\/management-of-non-neurogenic-male-luts\/chapter\/disease-management"},{"issue":"6","key":"6122_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","volume":"64","author":"B Djavan","year":"2004","unstructured":"Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 64(6):1081\u20131088","journal-title":"Urology"},{"issue":"33","key":"6122_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000026955","volume":"100","author":"J Guo","year":"2021","unstructured":"Guo J, Tang R (2021) Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a systematic review and meta-analysis. Medicine 100(33):e26955","journal-title":"Medicine"},{"issue":"5","key":"6122_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Int J Surg 8(5):336\u2013341","journal-title":"Int J Surg"},{"issue":"2","key":"6122_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2174\/157488709788186021","volume":"4","author":"VW Berger","year":"2009","unstructured":"Berger VW, Alperson SY (2009) A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials 4(2):79\u201388","journal-title":"Rev Recent Clin Trials"},{"key":"6122_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"issue":"20","key":"6122_CR27","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","volume":"23","author":"G Lu","year":"2004","unstructured":"Lu G, Ades AE (2004) Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 23(20):3105\u20133124","journal-title":"Stat Med"},{"key":"6122_CR28","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1023\/A:1008929526011","volume":"10","author":"DJ Lunn","year":"2000","unstructured":"Lunn DJ, Thomas A, Best N, Spiegelhalter D (2000) WinBUGS \u2014 a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 10:325\u2013337","journal-title":"Stat Comput"},{"issue":"4","key":"6122_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter DJ, Best NG, Carlin BP, Van Der Linde A (2002) Bayesian measures of model complexity and fit. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 64(4):583\u2013639","journal-title":"Journal of the Royal Statistical Society: Series B (Statistical Methodology)"},{"issue":"9","key":"6122_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105653","volume":"9","author":"DA Patel","year":"2014","unstructured":"Patel DA, Snedecor SJ, Tang WY et al (2014) 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1\u2013infected patients: a systematic review and network meta-analysis. PLoS ONE 9(9):e105653","journal-title":"PLoS ONE"},{"key":"6122_CR31","unstructured":"American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH). Revised, 2010 (2010) Available from: https:\/\/www.auanet.org\/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)"},{"issue":"6","key":"6122_CR32","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.juro.2013.05.058","volume":"190","author":"CP Filson","year":"2013","unstructured":"Filson CP, Hollingsworth JM, Clemens JQ, Wei JT (2013) The efficacy and safety of combined therapy with alpha-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol 190(6):2153\u20132160","journal-title":"J Urol"},{"issue":"6","key":"6122_CR33","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","volume":"69","author":"F Fusco","year":"2016","unstructured":"Fusco F, Palmieri A, Ficarra V et al (2016) A1-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 69(6):1091\u20131101","journal-title":"Eur Urol"},{"issue":"6","key":"6122_CR34","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M, Ficarra V, Sebastianelli A et al (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta\u2010analysis. J Sex Med 11(6):1554\u20131566","journal-title":"J Sex Med"},{"issue":"10","key":"6122_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","volume":"62","author":"JC Nickel","year":"2008","unstructured":"Nickel JC, Sander S, Moon TD (2008) A meta-analysis of the vascular-related safety profile and efficacy of \u03b1-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 62(10):1547\u20131559","journal-title":"Int J Clin Pract"},{"issue":"2","key":"6122_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3349\/ymj.2016.57.2.407","volume":"57","author":"SR Shim","year":"2016","unstructured":"Shim SR, Kim JH, Chang IH et al (2016) Is Tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers? A meta-analysis and a moderator focused study. Yonsei Med J 57(2):407\u2013418","journal-title":"Yonsei Med J"},{"issue":"4","key":"6122_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.ophtha.2010.08.039","volume":"118","author":"IP Chatziralli","year":"2011","unstructured":"Chatziralli IP, Sergentanis TN (2011) Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 118(4):730\u2013735","journal-title":"Ophthalmology"},{"issue":"1","key":"6122_CR38","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12877-022-03415-7","volume":"22","author":"F Mansbart","year":"2022","unstructured":"Mansbart F, Kienberger G, S\u00f6nnichsen A, Mann E (2022) Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing. BMC Geriatr 22(1):771","journal-title":"BMC Geriatr"},{"issue":"2","key":"6122_CR39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1442-2042.2007.01502.x","volume":"14","author":"Z Xue","year":"2007","unstructured":"Xue Z, Zhang Y, Ding Q, He Z, Wang J, Xu K (2007) Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: a study in Chinese patients. Int J Urol 14(2):118\u2013122","journal-title":"Int J Urol"},{"issue":"3","key":"6122_CR40","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.urology.2011.04.038","volume":"78","author":"K Zhang","year":"2011","unstructured":"Zhang K, Yu W, Jin J et al (2011) Effect of doxazosin gastrointestinal therapeutic system 4 mg vs Tamsulosin 0.2 mg on nocturia in Chinese men with lower urinary tract symptoms: a prospective, multicenter, randomized, open, parallel study. Urology 78(3):636\u2013640","journal-title":"Urology"},{"issue":"1","key":"6122_CR41","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1046\/j.1464-410X.2003.03077.x","volume":"91","author":"RS Kirby","year":"2003","unstructured":"Kirby RS (2003) A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia. BJU Int 91(1):41\u201344","journal-title":"BJU Int"},{"issue":"1","key":"6122_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/j.1368-5031.2004.0031.x","volume":"58","author":"RS Kirby","year":"2004","unstructured":"Kirby RS, Quinn S, Mallen S, Jensen D (2004) Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis. Int J Clin Pract 58(1):6\u201310","journal-title":"Int J Clin Pract"},{"issue":"10","key":"6122_CR43","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1742-1241.2006.01107.x","volume":"60","author":"ACL Pompeo","year":"2006","unstructured":"Pompeo ACL, Rosenblatt C, Bertero E et al (2006) A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract 60(10):1172\u20131177","journal-title":"Int J Clin Pract"},{"issue":"11","key":"6122_CR44","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1442-2042.2006.01590.x","volume":"13","author":"D Rahardjo","year":"2006","unstructured":"Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I (2006) Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol 13(11):1405\u20131409","journal-title":"Int J Urol"},{"issue":"5","key":"6122_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1177\/0272989X12455847","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Welton NJ, Sutton AJ, Caldwell DM, Lu G, Ades AE (2013) Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33(5):641\u2013656","journal-title":"Med Decis Making"},{"key":"6122_CR46","doi-asserted-by":"crossref","unstructured":"Abrams P, Schulman CC, Vaage S, European Tamsulosin Study Group (1995) Tamsulosin, a selective \u03b11C-adrenoceptor antagonist: a randomized controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol 76:325\u2013336","DOI":"10.1111\/j.1464-410X.1995.tb07709.x"},{"issue":"4","key":"6122_CR47","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1046\/j.1464-410X.1997.00380.x","volume":"80","author":"P Abrams","year":"1997","unstructured":"Abrams P, Speakman M, Stott M, Arkell D, Pocock R (1997) A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80(4):587\u2013596","journal-title":"Br J Urol"},{"issue":"1","key":"6122_CR48","first-page":"41","volume":"70","author":"H Akan","year":"1998","unstructured":"Akan H, Basar M, Dalva I, Basar H (1998) The early effects of doxazosin on benign prostatic hyperplasia. Archivio italiano di urologia, andrologia\u202f: organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica 70(1):41\u201344","journal-title":"Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica"},{"issue":"4","key":"6122_CR49","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1159\/000020315","volume":"38","author":"M Andersen","year":"2000","unstructured":"Andersen M, Dahlstrand C, H\u00f8ye K (2000) Double\u2013blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 38(4):400\u2013409","journal-title":"Eur Urol"},{"issue":"24","key":"6122_CR50","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.4103\/0366-6999.195461","volume":"129","author":"J-L Cai","year":"2016","unstructured":"Cai J-L, Zhou Z, Yang Y, Yan Y-F, Jing S, Na Y-Q (2016) Efficacy and safety of medium-to-long-term use of tolterodine extended release with or without tamsulosin in patients with benign prostate hyperplasia and larger prostate size: a double-blind, placebo-controlled, randomized clinical trial. Chin Med J 129(24):2899\u20132906","journal-title":"Chin Med J"},{"issue":"3","key":"6122_CR51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TLJ, Wirth M, Koldewijn E, Fern\u00e1ndez Fern\u00e1ndez E (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59(3):342\u2013352","journal-title":"Eur Urol"},{"issue":"2","key":"6122_CR52","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eursup.2004.10.010","volume":"4","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Al-Shukri SH, Gattegno B et al (2005) Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH): efficacy and tolerability in a placebo and active comparator controlled phase 3a study. Eur Urol Suppl 4(2):33\u201344","journal-title":"Eur Urol Suppl"},{"issue":"2","key":"6122_CR53","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.eursup.2004.10.009","volume":"4","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Lorenz J, Mortensen R et al (2005) Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH): efficacy and tolerability in a phase 2b dose-response study. Eur Urol Suppl 4(2):25\u201332","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"6122_CR54","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1464-410X.1994.tb16546.x","volume":"74","author":"CR Chapple","year":"1994","unstructured":"Chapple CR, Carter P, Christmas TJ et al (1994) A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 74(1):50\u201356","journal-title":"Br J Urol"},{"issue":"2","key":"6122_CR55","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eursup.2004.12.001","volume":"4","author":"B Djavan","year":"2005","unstructured":"Djavan B, Milani S, Davies J, Bolodeoku J (2005) The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 4(2):61\u201368","journal-title":"Eur Urol Suppl"},{"issue":"1","key":"6122_CR56","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0022-5347(01)67240-9","volume":"154","author":"A Fawzy","year":"1995","unstructured":"Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154(1):105\u2013109","journal-title":"J Urol"},{"issue":"1","key":"6122_CR57","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0022-5347(01)67243-4","volume":"154","author":"JY Gillenwater","year":"1995","unstructured":"Gillenwater JY, Conn RL, Chrysant SG et al (1995) Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study. J Urol 154(1):110\u2013115","journal-title":"J Urol"},{"issue":"9","key":"6122_CR58","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1464-410X.2008.07761.x","volume":"102","author":"SA Kaplan","year":"2008","unstructured":"Kaplan SA, Roehrborn CG, Chancellor M, Carlsson M, Bavendam T, Guan Z (2008) Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 102(9):1133\u20131139","journal-title":"BJU Int"},{"issue":"19","key":"6122_CR59","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296(19):2319\u20132328","journal-title":"JAMA"},{"issue":"5","key":"6122_CR60","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K, Yoshida M, Homma Y (2006) Silodosin, a new \u03b11A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98(5):1019\u20131024","journal-title":"BJU Int"},{"issue":"4","key":"6122_CR61","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S0022-5347(17)39620-9","volume":"144","author":"K Kawabe","year":"1990","unstructured":"Kawabe K, Ueno A, Takimoto Y, Aso Y, Kato H (1990) Use of an &amp;#x3b1;1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J Urol 144(4):908\u2013911","journal-title":"J Urol"},{"issue":"2","key":"6122_CR62","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1757-5672.2011.00088.x","volume":"3","author":"SC Kim","year":"2011","unstructured":"Kim SC, Park JK, Kim SW et al (2011) Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Lower Urinary Tract Symptoms 3(2):86\u201393","journal-title":"Lower Urinary Tract Symptoms"},{"issue":"1","key":"6122_CR63","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0090-4295(02)02114-3","volume":"61","author":"RS Kirby","year":"2003","unstructured":"Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61(1):119\u2013126","journal-title":"Urology"},{"issue":"6","key":"6122_CR64","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0090-4295(98)00126-5","volume":"51","author":"H Lepor","year":"1998","unstructured":"Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 51(6):892\u2013900","journal-title":"Urology"},{"issue":"6","key":"6122_CR65","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0090-4295(98)00127-7","volume":"51","author":"H Lepor","year":"1998","unstructured":"Lepor H (1998) Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 51(6):901\u2013906","journal-title":"Urology"},{"issue":"25","key":"6122_CR66","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa030656","volume":"349","author":"JD McConnell","year":"2003","unstructured":"McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349(25):2387\u20132398","journal-title":"N Engl J Med"},{"issue":"3","key":"6122_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1046\/j.1442-2034.2003.00181.x","volume":"7","author":"NK Mohanty","year":"2003","unstructured":"Mohanty NK, Nayak RL, Malhotra V, Arora RP (2003) A double-blind placebo controlled study of tamsulosin in the management of benign prostatic hyperplasia in an Indian population. Ann Coll Surg Hong Kong 7(3):88\u201393","journal-title":"Ann Coll Surg Hong Kong"},{"issue":"5","key":"6122_CR68","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","volume":"160","author":"P Narayan","year":"1998","unstructured":"Narayan P, Tewari A (1998) A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160(5):1701\u20131706","journal-title":"J Urol"},{"issue":"7","key":"6122_CR69","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/j.1464-410X.2005.05456.x","volume":"95","author":"J Nordling","year":"2005","unstructured":"Nordling J (2005) Efficacy and safety of two doses (10 and 15\u2003mg) of alfuzosin or tamsulosin (0.4\u2003mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 95(7):1006\u20131012","journal-title":"BJU Int"},{"issue":"5","key":"6122_CR70","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.eururo.2012.01.013","volume":"61","author":"M Oelke","year":"2012","unstructured":"Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L (2012) Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 61(5):917\u2013925","journal-title":"Eur Urol"},{"issue":"4","key":"6122_CR71","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1023\/A:1007111211130","volume":"31","author":"I Ozbey","year":"1999","unstructured":"Ozbey I, Aksoy Y, Polat O, Bicgi O, Demirel A, Okyar G (1999) Effects of doxazosin in men with benign prostatic hyperplasia: urodynamic assessment. Int Urol Nephrol 31(4):471\u2013479","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"6122_CR72","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000137643","volume":"81","author":"L Prieto","year":"2008","unstructured":"Prieto L, Romero J, L\u00f3pez C, Ortiz M, Pacheco JJ (2008) Efficacy of doxazosin in the treatment of acute urinary retention due to benign prostate hyperplasia. Urol Int 81(1):66\u201371","journal-title":"Urol Int"},{"key":"6122_CR73","unstructured":"Rollema HJ, Rosier P, Janknegt RA, van Mastrigt R (1991) Efficacy of alpha-blocker (doxazosin) in BPH appraised by pressure-flow (CLIM) analysis [abstract]. Neurourol Urodyn 295\u2013296"},{"issue":"1","key":"6122_CR74","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.urology.2013.03.026","volume":"82","author":"A Shelbaia","year":"2013","unstructured":"Shelbaia A, Elsaied WM, Elghamrawy H, Abdullah A, Salaheldin M (2013) Effect of selective alpha-blocker tamsulosin on erectile function in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Urology 82(1):130\u2013135","journal-title":"Urology"},{"issue":"Suppl 4","key":"6122_CR75","first-page":"87","volume":"5","author":"P Singh","year":"2012","unstructured":"Singh P, Singh A, Indurkar M, Bhupendra R (2012) Efficacy and safety of tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. Asian J Pharm Clin Res 5(Suppl 4):87\u201391","journal-title":"Asian J Pharm Clin Res"},{"issue":"6","key":"6122_CR76","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","volume":"64","author":"P van Kerrebroeck","year":"2013","unstructured":"van Kerrebroeck P, Chapple C, Drogendijk T et al (2013) Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial. Eur Urol 64(6):1003\u20131012","journal-title":"Eur Urol"},{"issue":"3","key":"6122_CR77","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","volume":"64","author":"P Van Kerrebroeck","year":"2013","unstructured":"Van Kerrebroeck P, Haab F, Angulo JC et al (2013) Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN). Eur Urol 64(3):398\u2013407","journal-title":"Eur Urol"},{"issue":"2","key":"6122_CR78","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1442-2042.2012.03130.x","volume":"20","author":"O Yokoyama","year":"2013","unstructured":"Yokoyama O, Yoshida M, Kim SC et al (2013) Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo- and tamsulosin-controlled 12-week study in Asian men. Int J Urol 20(2):193\u2013201","journal-title":"Int J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06122-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06122-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:01:25Z","timestamp":1767722485000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06122-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6122"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06122-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Oelke received speaker honoraria for Male LUTS\/BPH from Astellas, GlaxoSmithKline, Lilly, Pfizer, SAJA-Pharma and SUN Pharma, was advisory board member of Apogepha, Astellas, GlaxoSmithKline, Lilly, Mundipharma, Pierre-Fabre, Pfizer and Recordati, received research grants from Astellas, Intuitive and Pfizer, and participated in clinical trials from Apogepha, Astellas, GlaxoSmithKline, Lilly, Pfizer, Recordati and Dr. Schwabe GmbH. M. Oelke is currently employed at Spital Thurgau AG, Thurgau, Switzerland. J.N. Cornu is a consultant companies like Boston scientific, Medtronic, Pfizer. He is a paid speaker and participated as advisory boards for companies like Boston scientific and Medtronic. He has received travel grants from Stimuli technology, Procept biorobotics. I. Chopra is former employee of Pharmerit International, Bethesda, MD, USA. T Herrmann is currently employed at Spital Thurgau AG, Thurgau, Switzerland. T. Hassan is employee of Viatris Inc., New York, NY, USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This review article does not contain studies with human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"78"}}